Publication date: Jan 28, 2025
In this population-based study, we examined the risk of nontuberculous mycobacterial disease associated with immune checkpoint inhibitors among people with cancer. Using a nested case-control design, we identified 184 cases and 714 matched controls; there was no significant association on conditional logistic regression (adjusted odds ratio, 0. 51 [95% confidence interval, .17-1. 50]; P = .22).
Open Access PDF
| Concepts | Keywords |
|---|---|
| Cancer | cancer |
| Drugs | immune checkpoint inhibitors |
| Immune | nontuberculous mycobacterial disease |
| Mycobacterial | population study |
| tuberculosis |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Infections |
| disease | MESH | cancer |
| disease | MESH | Infectious Diseases |
| pathway | REACTOME | Reproduction |
| drug | DRUGBANK | Coenzyme M |
| pathway | REACTOME | Translation |
| disease | IDO | site |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| disease | IDO | cell |
| disease | MESH | Hodgkin lymphoma |
| disease | IDO | blood |
| disease | IDO | infection |
| disease | MESH | asthma |
| pathway | KEGG | Asthma |
| disease | MESH | COPD |
| disease | MESH | rheumatoid arthritis |
| pathway | KEGG | Rheumatoid arthritis |
| disease | MESH | gastroesophageal reflux disease |